Verve Therapeutics

Verve Therapeutics

Biotechnology Research

Boston, Massachusetts 30,802 followers

We are on a mission to protect the world from cardiovascular disease.

About us

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.

Website
http://www.vervetx.com
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Boston, Massachusetts
Type
Privately Held
Founded
2018

Locations

  • Primary

    201 Brookline Ave

    Suite 601

    Boston, Massachusetts 02215, US

    Get directions

Employees at Verve Therapeutics

Updates

Similar pages

Browse jobs

Funding

Verve Therapeutics 5 total rounds

Last Round

Post IPO equity

US$ 143.8M

See more info on crunchbase